Sign Up to like & get
recommendations!
2
Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-162
Abstract: Background N of 1 treatment paradigms represent the pinnacle of personalized medicine in which a patient’s tumors are profiled to guide treatment. Low-grade serous ovarian cancer (LGSC) is a distinct subtype of ovarian cancer, comprising…
read more here.
Keywords:
proof concept;
bh3 profiling;
patient;
viability ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-131101
Abstract: BCL-2 antagonist venetoclax combined with hypomethylating agents or low-dose cytarabine is a new standard of care for treatment-naive elderly or unfit AML patients. Despite the striking overall response of 70%, only 30% achieved MRD negative…
read more here.
Keywords:
combination;
venetoclax;
bh3 profiling;
research funding ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2021 at "Cancers"
DOI: 10.3390/cancers13051002
Abstract: Simple Summary The BCL2 protein is expressed in many non-Hodgkin lymphomas (NHLs) as well as associated leukemias, e.g., chronic lymphocytic leukemia (CLL). It functions as a cell survival protein that reduces that ability of a…
read more here.
Keywords:
lymphoma;
venetoclax;
apoptosis;
non hodgkin ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Oncology Reports"
DOI: 10.3892/or.2019.7373
Abstract: 5-Fluorouracil (5-FU) is a cytotoxic anticancer drug commonly used for patients with advanced colon cancer. This drug effectively reduces the size of tumors to a certain degree; however, cancer cells can gradually acquire resistance, resulting…
read more here.
Keywords:
bh3 profiling;
resistance;
colon cancer;
resistant colon ... See more keywords